Kristine M. Ball, a member of the board of directors at Oruka Therapeutics, Inc. (NASDAQ:ORKA), disposed of 17,990 shares of the company's common stock on November 12, 2026, according to a regulatory filing. The total value of the sale was approximately $1,888,748. The transaction was executed in multiple lots with prices spanning from $101.62 to $107.00 per share.
The sale came immediately after Ball exercised stock options to acquire 18,000 shares at $6.84 per share, a total cost of $123,120. Those options vest over time, with one-quarter of the shares vesting on May 7, 2025, and the remainder vesting in monthly installments over the following 48 months. The sale was conducted under a Rule 10b5-1 trading plan that Ball had established on August 12, 2026, well before the transactions occurred.
Details of the share disposal reveal a tiered execution:
- 1,196 shares were sold at prices between $101.62 and $102.61.
- 1,300 shares were sold between $102.66 and $103.65.
- 2,039 shares were sold between $103.69 and $104.65.
- 10,765 shares were sold between $104.76 and $105.75.
- 2,500 shares were sold between $105.76 and $106.46.
- 200 shares were sold between $106.97 and $107.00.
Following these transactions, Ball directly holds no shares of Oruka Therapeutics common stock.
The stock currently trades at $105.35, having delivered a 289% return over the past year. According to an analysis, the company appears overvalued at current levels, with the stock's strong momentum highlighted despite profitability concerns. Investors can access additional ProTips and comprehensive Fair Value analysis on the platform.
Oruka Therapeutics has recently reported notable developments in its clinical trials. The company announced positive results from its EVERLAST-B Phase 2b trial of ORKA-001, a monoclonal antibody for moderate-to-severe plaque psoriasis. The trial, which included 187 patients, showed promising outcomes, with the 600mg dose achieving a 61% PASI-100 response, indicating complete skin clearance in 28 of 46 patients. H.C. Wainwright and Guggenheim both reiterated Buy ratings for Oruka Therapeutics, setting price targets of $120 and $200, respectively, based on these results. Piper Sandler also maintained an Overweight rating with a $180 price target, highlighting the company's strong pipeline of drug candidates. Additionally, the EVERLAST-A Phase 2a trial showed improved PASI 100 and PASI 90 response rates at Week 28, with no injection-site reactions reported. These developments have kept analysts optimistic about Oruka's future prospects, despite some fluctuations in the stock market.